NCT03895684View on ClinicalTrials.gov

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

SP-2577 Seclidemstat

Dose escalation and dose expansion of SP-2577.

Trial Locations (2)

85258

HonorHealth, Scottsdale

90403

Sarcoma Oncology Research Center, Santa Monica

All Listed Sponsors
lead

Salarius Pharmaceuticals, LLC

INDUSTRY

NCT03895684 - Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter